Skräddarsydda proteiner för tumörmålsökning med radionuklider för diagnostik och terapi
Tidsperiod: 2020-01-01 till 2023-12-31
Projektledare: Vladimir Tolmachev
Medarbetare: Anna Orlova, Jens Sörensen, Sophia Hober, Amelie Eriksson Karlström, SERGEY DEYEV
Budget: 4 800 000 SEK
The purpose of the project is to investigate factors influencing targeted delivery of radionuclides using engineered scaffold proteins (ESP). The ultimate goal is to provide rationale for molecular design of novel agents for radionuclide imaging and therapy of cancer.Engineered scaffold proteins (ESP) are new type of targeting vectors capable to deliver radionuclides to malignant tumors by specific recognition of cancer-associated molecular abnormalities on a surface of malignant cells. Non-invasive in vivo radionuclide imaging of such abnormalities may enable selection of a specific therapy for a given patient (personalized medicine). The use of cytotoxic nuclides can be used for radionuclide therapy. Our previous studies demonstrated that ESP are better targeting vectors than monoclonal antibodies.The project is multidisciplinary and translational. The production of ESP and will be performed in collaboration with researches from the Royal Institute of Technology-TKH (Stockholm) and Institute of Bioorganic Chemistry (Moscow). Radiolabeling, in vitro and in vivo studies will be performed in the applicant’s lab, where relevant methodology is well established. Clinical translation is foreseen in Uppsala University Hospital. The project should be accomplished in 5 years. This project may result in development of improved diagnostic and therapeutic agents for disseminated HER2-positive trastuzumab-resistant and triple negative breast cancers.